Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose

<b>Background and Aim:</b> Controlling the hepatic inflammation of metabolic dysfunction-associated steatotic liver disease (MASLD) is important to prevent serious condition. Pemafibrate, a selective peroxisome proliferator-activated receptor-α modulator, has demonstrated effectiveness a...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Satoshi Shinozaki, Kouichi Miura, Toshiyuki Tahara, Hironori Yamamoto
Formatua: Artikulua
Hizkuntza:English
Argitaratua: MDPI AG 2025-02-01
Saila:Metabolites
Gaiak:
non-alcoholic fatty liver disease
non-alcoholic steatohepatitis
pemafibrate
dyslipidemia
metabolic dysfunction-associated steatotic liver disease
Sarrera elektronikoa:https://www.mdpi.com/2218-1989/15/2/100

Internet

https://www.mdpi.com/2218-1989/15/2/100

Antzeko izenburuak